Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158520 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02158520 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 24 participants.
The verdict
NCT02158520, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop the growth of tumor cells by binding to a protein called vascular endothelial growth factor (VEGF) and by preventing the growth of new blood vessels that tumors need to grow. Ipilimumab blocks a substance called cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) on the surface of T cells and may help the immune system kill cancer cells. It is not yet known whether nab-paclitaxel and bevacizumab is more effective than ipilimumab in treating melanoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Nab-paclitaxel
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Bevacizumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10-18 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02158520
The ClinicalTrials.gov registry entry for NCT02158520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02158520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02158520 about?
NCT02158520 is a clinical study titled "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery". This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tum...
What is the current status of trial NCT02158520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-10-18. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT02158520?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nab-paclitaxel (DRUG), Ipilimumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02158520?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.